Ordonez Claudia 4

4 · Keros Therapeutics, Inc. · Filed Feb 16, 2021

Form 4

Period: 2021-02-11

Chief Medical Officer

Transactions

Sale
Common Stock
2021-02-11$64.17/sh−312$20,021→ 513 total
Exercise/Conversion
Employee Stock Option (right to buy)
2021-02-11−1,000→ 102,211 total
Exercise: $0.48Exp: 2029-09-18→ Common Stock (1,000 underlying)
Sale
Common Stock
2021-02-11$63.10/sh−175$11,043→ 825 total
Sale
Common Stock
2021-02-11$66.19/sh−295$19,526→ 2 total
Exercise/Conversion
Common Stock
2021-02-11$0.48/sh+1,000$480→ 1,000 total
Sale
Common Stock
2021-02-11$65.35/sh−216$14,116→ 297 total
Sale
Common Stock
2021-02-11$68.05/sh−2$136→ 0 total

Footnotes (6)

[F1]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.
[F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $62.71 to $63.51 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3), (4) and (5).
[F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $63.775 to $64.535 inclusive.
[F4]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $64.855 to $65.73 inclusive.
[F5]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $66.00 to $66.69 inclusive.
[F6]One-quarter (1/4th) of the shares subject to the option shall vest on September 16, 2020, and one-twelfth (1/12th) of the remaining shares subject to the option shall vest in equal quarterly installments thereafter, subject to the Reporting Person continuing to provide service through each such date.

Documents

1 file